Femasys Inc
NASDAQ:FEMY
Net Margin
Femasys Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Femasys Inc
NASDAQ:FEMY
|
23m USD |
-1 243%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
230.3B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
182.6B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
149.8B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
143.5B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.7B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.8B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48.3B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
43.5B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.3B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
275.5B CNY |
31%
|
Femasys Inc
Glance View
Femasys, Inc. operates as a medical device company that focuses on women's healthcare. The company is headquartered in Suwanee, Georgia. The company went IPO on 2021-06-18. The firm is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. FemaSeed is an artificial insemination infertility treatment. The firm also offers FemVue Saline-Air device for diagnosis of infertility and FemCerv Endocervical Sampler for diagnosis of cervical cancer. FemCerv is a sterile, single-use disposable endocervical curettage product that can be used to sample cervical cells and tissue, including in support of further testing following an abnormal Pap test to assess for any problems such as cancer, in a relatively pain-free office procedure.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Femasys Inc's most recent financial statements, the company has Net Margin of -1 242.6%.
You don't have any saved screeners yet